Ética & Regulação
Could Texas A&M's Nasal Spray Transform Cognitive Decline Treatment?
Dr. Adrian Vale
LLM, AI Agents & AI Infrastructure Specialist
4 min read
Listen to Article
AI automated narration
LLM, AI Agents & AI Infrastructure Specialist
Researchers at Texas A&M University developed a nasal spray using extracellular vesicles (EVs) that improved cognitive function by 30% and reduced brain inflammation in aging mice after just two doses. This breakthrough offers hope for combating brain aging and neurodegenerative diseases like Alzheimer’s and Parkinson’s, with human trials planned by 2028.
Brain aging is a natural process involving the gradual decline of cognitive abilities such as memory, learning, and reasoning. According to the World Health Organization (WHO), approximately 50 million people worldwide are affected by neurodegenerative diseases like Alzheimer’s and Parkinson’s as of 2026. With the aging global population, the search for innovative solutions to delay or reverse age-related cognitive decline has become a pressing priority.
A groundbreaking development by researchers at Texas A&M University introduces a novel approach: a nasal spray containing extracellular vesicles (EVs), which has shown the potential to reverse brain aging in preclinical trials on mice.
Extracellular vesicles are tiny, naturally occurring structures released by cells that play a vital role in communication and molecular transport within the body. They exhibit anti-inflammatory and regenerative properties, making them an attractive candidate for mitigating cellular damage caused by aging, such as mitochondrial dysfunction.
In a study conducted on 18-month-old mice (equivalent to approximately 60-year-old humans):
The nasal spray's effectiveness is attributed to the ability of EVs to cross the blood-brain barrier, delivering targeted therapeutic effects directly to the brain. These findings, reported by Neuroscience News, suggest that EV-based therapies could not only slow but potentially reverse cognitive decline associated with aging.
The potential applications of this technology extend beyond normal aging. The nasal spray could be a game-changer in treating neurodegenerative conditions such as Alzheimer’s, Parkinson’s, and various forms of dementia. Projections indicate that early intervention in such diseases could increase healthy life expectancy by 15%.
However, several challenges must be addressed before clinical implementation in humans:
The possibility of reversing brain aging raises profound ethical questions:
The researchers at Texas A&M plan to address these issues as they prepare for clinical trials within the next two years. These trials, expected to conclude by 2028, will evaluate the treatment's safety and effectiveness in humans.
The next phase involves human clinical trials, scheduled to begin within two years. If successful, the nasal spray could be commercialized as early as 2028, offering new hope for addressing aging and neurodegenerative diseases. In addition, ongoing research into extracellular vesicles may uncover broader applications in other medical fields, potentially revolutionizing treatments for a wide range of health conditions.
The nasal spray developed by Texas A&M uses extracellular vesicles (EVs) to reverse brain aging, improve memory, and reduce inflammation, as demonstrated in preclinical tests on mice.
The nasal spray improved cognitive function by 30% and reduced brain inflammation in aging mice after just two doses, showing potential to reverse brain aging.
Texas A&M researchers plan to start clinical trials in humans within the next two years, with potential commercialization by 2028 if proven safe and effective.
💡 Dica Pro: Extracellular vesicles (EVs) have shown promise in regenerative medicine beyond neurological applications. Researchers are currently investigating their potential in treating cardiovascular diseases, immune modulation, and even targeted cancer therapies.
